Skip to main content

Table 6 Deterministic Sensitivity Analysis (ICERs of assessed antipsychotics versus haloperidol)

From: Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses

Parameter Incremental Cost (€) Incremental QALYs ICER versus haloperidol (€/QALY gained)
Base case (BC)    
Amisulpride 925 0.0101 91,584
Aripiprazole 1,390 0.0147 94,558
Olanzapine 574 0.0243 23,621
Paliperidone ER -260 0.0341 Dominant
Risperidone -128 0.0105 Dominant
Probability of relapse +20% BC   
Amisulpride 795 0.0099 80,303
Aripiprazole 1,227 0.0144 85,208
Olanzapine 317 0.0258 12,287
Paliperidone ER -632 0.0373 Dominant
Risperidone -279 0.0107 Dominant
Probability of relapse -20% BC   
Amisulpride 986 0.0150 65,733
Aripiprazole 1,495 0.0131 114,122
Olanzapine 773 0.0238 32,479
Paliperidone ER 55 0.0326 1,687
Risperidone -35 0.0099 Dominant
Probability of discontinuation due to AE +20% BC  
Amisulpride 861 0.0097 88,763
Aripiprazole 1,356 0.0130 104,308
Olanzapine 516 0.0238 21,681
Paliperidone ER -287 0.0319 Dominant
Risperidone -184 0.0099 Dominant
Probability of discontinuation due to AE -20% BC  
Amisulpride 930 0.0104 89,423
Aripiprazole 1,373 0.0163 84,233
Olanzapine 575 0.0249 23,092
Paliperidone ER -291 0.0362 Dominant
Risperidone -141 0.0114 Dominant
Probability of discontinuation due to other reasons +20% BC
Amisulpride 868 0.0094 92,340
Aripiprazole 1,358 0.0135 100,593
Olanzapine 490 0.0243 20,165
Paliperidone ER -364 0.0349 Dominant
Risperidone -211 0.0100 Dominant
Probability of discontinuation due to other reasons -20% BC  
Amisulpride 923 0.0105 87,905
Aripiprazole 1,363 0.0157 86,815
Olanzapine 601 0.0242 24,835
Paliperidone ER -213 0.0332 Dominant
Risperidone -103 0.0106 Dominant
  1. Dominant: strategy with higher effectiveness (QALYs) and lower cost